全文获取类型
收费全文 | 36920篇 |
免费 | 3002篇 |
国内免费 | 207篇 |
学科分类
医药卫生 | 40129篇 |
出版年
2023年 | 260篇 |
2022年 | 427篇 |
2021年 | 920篇 |
2020年 | 589篇 |
2019年 | 856篇 |
2018年 | 1035篇 |
2017年 | 774篇 |
2016年 | 868篇 |
2015年 | 927篇 |
2014年 | 1259篇 |
2013年 | 1550篇 |
2012年 | 2401篇 |
2011年 | 2506篇 |
2010年 | 1446篇 |
2009年 | 1276篇 |
2008年 | 2142篇 |
2007年 | 2118篇 |
2006年 | 1983篇 |
2005年 | 1883篇 |
2004年 | 1819篇 |
2003年 | 1636篇 |
2002年 | 1467篇 |
2001年 | 1221篇 |
2000年 | 1086篇 |
1999年 | 940篇 |
1998年 | 362篇 |
1997年 | 264篇 |
1996年 | 241篇 |
1995年 | 236篇 |
1994年 | 204篇 |
1993年 | 186篇 |
1992年 | 539篇 |
1991年 | 505篇 |
1990年 | 466篇 |
1989年 | 428篇 |
1988年 | 380篇 |
1987年 | 354篇 |
1986年 | 347篇 |
1985年 | 339篇 |
1984年 | 232篇 |
1983年 | 215篇 |
1982年 | 144篇 |
1981年 | 108篇 |
1980年 | 115篇 |
1979年 | 181篇 |
1978年 | 102篇 |
1977年 | 120篇 |
1976年 | 78篇 |
1974年 | 93篇 |
1973年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 8 毫秒
1.
2.
3.
Dupuytren’s disease with severe finger contractures and recurrent contractures following previous surgery often have extensive skin involvement. In these severe cases, excision of the diseased chord along with the involved skin is a good option to reduce the risk of recurrance. The resulting skin defect can be covered with a full thickness skin graft (FTSG) or a cross finger flap. Cross finger flaps have donor finger morbidity and hence a full thickness graft is usually preferred. The FTSG extending to the midlateral margins on both sides of the finger reduces the risk of joint contracture due to graft shrinkage. Once the FTSG is sutured in place, the standard practice is to compress and secure the graft to its recipient bed with a tie-over dressing and this can be time consuming. We present a simple dressing technique to secure the FTSG without the need for a tie-over dressing. 相似文献
4.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
5.
6.
7.
8.
Prevalence of Potentially Inappropriate Prescribing Among Hong Kong Older Adults: A Comparison of the Beers 2003, Beers 2012, and Screening Tool of Older Person's Prescriptions and Screening Tool to Alert doctors to Right Treatment Criteria 下载免费PDF全文
9.
背景:对于脊椎以外的骨折而言,补充口服维生素D的预防作用和用量仍无定论。
目的:评估补充维生素D在预防老年髋骨骨折和非脊椎骨折方面的效果。
数据来源:使用MEDLINE、Cochrance对照试验记录(1960~2005年)以及EMBASE(1991-2005年),对英文和非英文文章进行系统回顾。通过与临床专家接触,通过检索美国社会骨和骨矿研究协会提供的参考文献和摘要(1995~2004年).进一步寻找更多的研究。检索词包括随机对照试验(randomized controlled trial,RCT)、临床对照试验、随机分配、双盲法、维生素D3、维生素D2;25-羟基维生素D、骨折、人类、老年、摔倒和骨密度。
研究选取:纳入的研究仅限于口服补充维生素D(维生素D3、维生素D2、补钙或不补钙)与补钙或安慰剂比较的双盲RCTs。试验于检查髋部骨折或非脊椎骨折的老年人(年龄≥60岁)中进行。数据提取:两位作者根据预先规定独立提取相关数据,其中包括研究质量指标。
数据综合:所有的汇总分析均以随机效应模型为基础。5项有关髋部骨折的RCTs(n=9294)和7项有关非脊椎骨折危险的RCTs(n=9820)符合我们的纳入标准。所有试验均使用了维生素D3。对髋部和非脊椎骨折预防研究的异质性亦进行观察,用低剂量(400IU/d)和高剂量(700~800IU/d)分别合并RCTs后异质性消失。与补钙或安慰剂相比,每天服700~800IU的维生素D可使髋部骨折的相对危险(relative risk,aa)下降26%(3项RCTs共计5572人;RR,0.74;95%可信区间[confidence interval,CI],0.61~0.88),使非脊椎骨折的相对危险下降23%(5项RCTs共计6098人;RR,0.77;95%CI,0.68~0.87)。每天服400IU的维生素D(2项RCTs共计3722人;髋部骨折RR,1.15;95%CI,0.88~1.50;非脊椎骨折RR,1.03;95%CI,0.86—1.24)未见明显获益。
结论:口服补充维生素D(700~800IU/d)可以降低尚能活动的老人或慈善机构收容的老年人发生髋部骨折和脊椎以外骨折的危险,每天口服400IU维生素D并不足以预防骨折。 相似文献
10.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献